J Appl Polym Sci 113: 2008-2017, 2009″
“Purpose: There is currently an ongoing paradigm shift in cancer treatment from intravenous (IV) chemotherapeutics to oral therapies. Additionally, the increased use of long-term maintenance therapy with oral targeted agents or chemotherapy is contributing to a shift toward a chronic-disease model. This shift is creating challenges and Vorinostat cell line responsibilities for health
care professionals in patient adherence management. This article will inform health care professionals of current trends and describe ways that they can overcome common barriers to adherence. A comprehensive review of recommendations and evidence derived from oncological studies describing adherence to oral targeted therapies and maintenance chemotherapy will provide guidance for the use of emerging oral maintenance
therapies.
Methods: Articles in the scientific literature were reviewed if published between January 1985 and November 2010. Searches were conducted using the PubMed database-search terms included “”oral therapy,”" Selleckchem CDK inhibitor “”chemotherapy,”" “”cancer,”" and “”adherence”" or “”compliance.”"
Results: The change from IV therapy administered and monitored in hospitals or clinics to self-administered outpatient oral treatments decreases the likelihood of adherence. Methods, such as patient education and monitoring and involvement of family or caretakers, can improve adherence in patients undergoing treatment.
Conclusions: At treatment onset, oncology nurses can engage patients directly in a collaborative dialogue, and when issues affecting adherence arise, oncology nurses may limit nonadherence by providing individually tailored educational material. A practical approach to patient education, along with building strong health care provider patient relationships, can help patients overcome nonadherence to new oral anticancer therapies and treatment paradigms.
(C) 2011 Elsevier Ltd. All rights reserved.”
“Our objective was to determine the association of serum adiponectin levels with the presence of IFG or DM in Filipinos. This case control study used sera of adult participants in the Philippines’ NNHeS: 2003-04. Subjects were divided into: normoglycaemic control, impaired fasting glucose, Galardin solubility dmso and type 2 diabetes mellitus. Seventy-seven prediabetic and 83 diabetic subjects were included in the prediabetic and diabetic groups, respectively. There was no significant difference in adiponectin values between control and prediabetic subjects. Diabetic subjects had significantly lower mean serum adiponectin levels (10.7 versus 14.2 mu g/ml, p= 0.0198) compared with age-and BMI-matched control subjects. Diabetic subjects were found most frequently (43.53%) in the lowest tertile (1.6-7.2 mu g/ml) and least frequently (20%) in the highest tertile (14-84 mu g/ml) of adiponectin values. We conclude that Filipinos with diabetes mellitus had significantly lower adiponectin levels compared with normoglycaemic subjects.